Actively Recruiting
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Led by City of Hope Medical Center · Updated on 2026-04-07
15
Participants Needed
1
Research Sites
127 weeks
Total Duration
On this page
Sponsors
C
City of Hope Medical Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.
CONDITIONS
Official Title
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide documented informed consent
- Be 18 years of age or older
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Have a diagnosis of multiple myeloma
- Have received at least 4 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
- Have received commercially available idecabtagene vicleucel (Abecma) between 30 and 90 days prior to enrollment
- Have experienced at least stable disease following idecabtagene vicleucel treatment
- Be fully recovered from acute toxic effects (except alopecia) to grade 1 or less from prior anti-cancer therapy
- Have an absolute neutrophil count (ANC) of at least 1,500/mm3 without recent filgrastim use
- Have platelet counts of at least 75,000/mm3 without recent transfusion
- Have total bilirubin levels at or below 1.5 times the upper limit of normal, unless Gilbert's disease is present
- Have aspartate aminotransferase (AST) levels at or below 3 times the upper limit of normal
- Have alanine transaminase (ALT) levels at or below 3 times the upper limit of normal
- Have alkaline phosphatase levels at or below 5 times the upper limit of normal
- Have creatinine clearance of 50 mL/min or greater
- Have oxygen saturation above 92% on room air
- Women of childbearing potential must have a negative pregnancy test
- Agree to follow the mezigdomide pregnancy prevention plan if applicable
You will not qualify if you...
- Prior exposure to mezigdomide (CC-92480)
- Use of other therapies besides mezigdomide
- Current or planned systemic immunosuppressive therapy, except low dose steroid replacement
- Use of CYP3A4/5 inhibitors or inducers
- Use of proton pump inhibitors
- Evidence of disease relapse
- Active involvement of the central nervous system
- Ongoing toxicities from CAR T cell therapy such as cytokine release syndrome or neurotoxicity
- History of allergic reactions to similar compounds
- Positive COVID-19 test or uncontrolled infections
- If HIV positive, CD4+ T cell count below 200
- Pregnant or breastfeeding females
- Any condition judged by the investigator to make participation unsafe
- Inability to comply with study procedures as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here